Free tool
FAERS Monitor: Aveed
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022219 or its brand name (Aveed, Testosterone Undecanoate). Reports on generic versions are filed under their own applications.
Reports
1,547
Serious
970
63% of reports
Hospitalization
283
Death reported
51
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective231
- cough153
- off label use134
- dyspnoea107
- pulmonary oil microembolism84
- blood testosterone decreased65
- fatigue57
- dizziness52
- injection site pain52
- hyperhidrosis48
- asthenia47
- malaise41
- inappropriate schedule of drug administration36
- inappropriate schedule of product administration36
- chest pain32
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 120 |
| 2015 | 232 |
| 2016 | 142 |
| 2017 | 98 |
| 2018 | 154 |
| 2019 | 140 |
| 2020 | 136 |
| 2021 | 104 |
| 2022 | 76 |
| 2023 | 62 |
| 2024 | 41 |
| 2025 | 132 |
| 2026 | 81 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,612 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pulmonary oil microembolismSignal | 84 | 49701.2 | 31420.8 | 886,725 |
| blood testosterone decreasedSignal | 65 | 130.4 | 102.7 | 8,144 |
| coughSignal | 153 | 7.4 | 6.4 | 855 |
| inappropriate schedule of drug administrationSignal | 36 | 6.9 | 5.0 | 176 |
| hyperhidrosisSignal | 48 | 5.1 | 3.8 | 154 |
| inappropriate schedule of product administrationSignal | 36 | 2.7 | 2.0 | 38 |
| dyspnoeaSignal | 107 | 2.6 | 2.1 | 104 |
| drug ineffectiveSignal | 231 | 2.4 | 2.1 | 196 |
| chest painSignal | 32 | 2.3 | 1.7 | 24 |
| injection site painSignal | 52 | 2.3 | 1.8 | 38 |
| off label useSignal | 134 | 2.1 | 1.8 | 77 |
| asthenia | 47 | 1.7 | 1.3 | 13 |
| dizziness | 52 | 1.4 | 1.1 | 6 |
| malaise | 41 | 1.3 | 0.9 | 2 |
| fatigue | 57 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.